NorthSea Therapeutics

Investment area
Novo Seeds
Region
Europe
Date of investment
December 2017

NorthSea Therapeutics is developing icosabutate a first-in-class Structurally Engineered Fatty Acid (SEFA) for Non-Alcoholic SteatoHepatitis or NASH. In addition, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases.

NorthSea Therapeutics

Investment area
Novo Seeds
Region
Europe
Date of investment
December 2017

NorthSea Therapeutics is developing icosabutate a first-in-class Structurally Engineered Fatty Acid (SEFA) for Non-Alcoholic SteatoHepatitis or NASH. In addition, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases.

NorthSea Therapeutics

Investment area
Novo Seeds
Region
Europe
Date of investment
December 2017

NorthSea Therapeutics is developing icosabutate a first-in-class Structurally Engineered Fatty Acid (SEFA) for Non-Alcoholic SteatoHepatitis or NASH. In addition, NorthSea is evaluating the potential of various SEFAs in other metabolic, inflammatory and fibrotic diseases.